Novel Mucosal Vaccine Platform for Broad Influenza Protection

Researchers at Georgia State University’s Institute for Biomedical Sciences have developed a novel mucosal vaccine platform designed to induce broad, protective immunity against a wide range of influenza virus infections. The study, announced on April 3, 2026, demonstrates that this approach can provide cross-protective immunity, offering a potential strategy to combat the rapid evolution of flu strains.

The vaccine platform utilizes cell-derived extracellular vesicles (EVs) to deliver antigens to the immune system. By using these vesicles, the researchers were able to display various human and avian influenza hemagglutinins (HAs) on the surface of the EVs in an inverted, or upside-down, orientation.

Targeting the Conserved HA Stalk

The effectiveness of this platform relies on the specific way the hemagglutinins are presented. In typical influenza viruses, the HA head is highly variable, which is why current vaccines often struggle to keep pace with mutating strains that elicit strain-specific responses.

By presenting the HA in an inverted manner, the vaccine exposes the conserved HA stalk region to the immune system while hiding the highly variable head. Because the stalk region remains relatively consistent across different influenza subtypes, targeting it can induce a more universal immune response.

Results from Animal Studies

In animal studies, the EV-based inverted HA vaccines produced several key immune responses:

• The elicitation of cross-reactive antibodies.
• The development of robust cellular immune responses.
• Complete protection against lethal challenges using different influenza subtypes.

These results indicate that the mucosal vaccine strategy is capable of protecting against diverse influenza virus infections, including subtypes such as H5N1 and H7N9.

Public Health Significance

The development of effective mucosal vaccines is considered crucial for the prevention of future epidemics and pandemics. Current flu vaccines frequently require updates to match circulating strains due to the virus’s ability to evolve quickly.

An innovative platform that induces universal immunity could reduce the reliance on frequent vaccine reformulations and provide more reliable protection against emerging avian and human influenza strains.

The use of cell-derived extracellular vesicles as a delivery mechanism allows the vaccine to mimic the natural structure of the virus while focusing the body’s defense on the most stable part of the viral protein.